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Key points 
iNKT cells were depleted in patients with advanced HIV infection, most significantly 
immunoregulatory CD4+ subsets.  
 
In patients with HIV-associated TB who developed TB-IRIS, iNKT cells were elevated with 
increased degranulation compared to non-IRIS patients, implicating iNKT cells in TB-IRIS 
immunopathology.    
  
MS with figures clean
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Abstract 41 
 42 
Rationale: Tuberculosis (TB) is the leading cause of mortality and morbidity in people living 43 
with HIV infection. HIV-infected patients with TB disease are at risk of the paradoxical TB-44 
associated immune reconstitution inflammatory syndrome (TB-IRIS) when they commence 45 
anti-retroviral therapy.  However, the pathophysiology is incompletely understood and specific 46 
therapy is lacking.  47 
 48 
Objectives: We investigated the hypothesis that invariant Natural Killer T (iNKT) cells 49 
contribute to innate immune dysfunction associated with TB-IRIS.  50 
 51 
Methods: In a cross-sectional study of 101 HIV-infected and -uninfected South African patients 52 
with active TB and controls, iNKT cells were enumerated using α-galactosylceramide-loaded 53 
CD1d tetramers and subsequently functionally characterised by flow cytometry. In a second 54 
study of 49 HIV-1-infected TB patients commencing anti-retroviral therapy, iNKT cells in TB-55 
IRIS patients with non-IRIS controls were compared longitudinally.  56 
 57 
Measurements and main results: Circulating iNKT cells were reduced in HIV-1 infection, most 58 
significantly the CD4+ subset, which was inversely associated with HIV-1 viral load. iNKT 59 
cells in HIV-associated TB had increased surface CD107a expression, indicating cytotoxic 60 
degranulation. Relatively increased iNKT cell frequency in HIV-infected patients with active 61 
TB was associated with development of TB-IRIS following anti-retroviral therapy initiation. 62 
iNKT cells in TB-IRIS were CD4+CD8- subset deplete and degranulated around the time of 63 
TB-IRIS onset. 64 
 65 
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Conclusions: Reduced iNKT cell CD4+ subsets as a result of HIV-1 infection may skew iNKT 66 
cell functionality towards cytotoxicity. Increased CD4- cytotoxic iNKT cells may contribute 67 
to immunopathology in TB-IRIS. 68 
 69 
 70 
  71 
 3 
Introduction 72 
Tuberculosis (TB) causes 1.6 million deaths annually and is the leading cause of death in HIV-73 
1 infected people (1). Anti-retroviral therapy (ART) naive HIV-1-infected patients with TB are 74 
at risk of the paradoxical TB immune reconstitution inflammatory syndrome (TB-IRIS) after 75 
commencing ART (2). Paradoxical TB-IRIS is characterised by an acute inflammatory 76 
response to Mycobacterium tuberculosis (Mtb) presenting as a clinical deterioration in a patient 77 
already receiving TB treatment, typically around two weeks post ART initiation (3). 78 
Paradoxical TB-IRIS is difficult to manage, frequently requiring non-specific 79 
immunosuppression with corticosteroids. Risk factors include disseminated TB and low CD4 80 
T cell count at ART initiation, but the pathophysiology is incompletely defined (4). Recent 81 
studies have identified potential contributory innate immune mechanisms, including neutrophil 82 
recruitment, inflammasome activation and proinflammatory cytokine excess (5-10). These 83 
potential mechanisms have been recently reviewed (2) 84 
 85 
Invariant natural killer T (iNKT) cells are a T cell subset that bridge innate and adaptive 86 
immunity, therefore are of interest in TB-IRIS pathogenesis (11). Distinct from NK cells and 87 
conventional T cells, iNKT cells express an invariant T cell receptor comprised of Vα24 and 88 
Vβ11 in humans, and specifically recognise CD1d-presented lipid antigens, responding on 89 
activation with rapid cytokine production. Additionally, iNKT cells recognise and are potently 90 
activated by the marine sponge glycolipid α-galactosylceramide (α-galcer), bound to CD1d 91 
(12, 13).  92 
 93 
Mtb cell wall is lipid-rich and therefore CD1d-presented molecules that activate iNKT cells 94 
may have a role in host immunity to Mtb (14, 15). In vitro, iNKT cells directly restricted Mtb 95 
growth and were bactericidal (16). In mice, augmenting iNKT cell responses with α-galcer 96 
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improved BCG vaccine efficacy and anti-tuberculosis treatment responses (17, 18). In non-97 
human primates, increased iNKT cell frequency was associated with TB resistance (19). In 98 
humans, a limited number of studies have demonstrated numerical and functional defects of 99 
iNKT cells in active TB (20-23).  100 
 101 
We previously reported elevated expression of cytotoxic mediators, perforin and granzyme B, 102 
in peripheral blood mononuclear cells (PBMC) in response to Mtb antigen stimulation and 103 
elevated frequencies of cytotoxic cells expressing CD3 and V24 T cell receptor in TB-IRIS 104 
patients compared to non-IRIS controls, suggesting that iNKT cells may play a role in TB-IRIS 105 
(24). Here, we systematically investigated iNKT cells in cross-sectional and longitudinal 106 
studies addressing the hypothesis that iNKT cell dysfunction contributes to TB-IRIS 107 
immunopathology. We describe for the first time iNKT cell aberration in HIV-associated TB 108 
disease and increased cytotoxic iNKT cells in TB-IRIS patients.  109 
 110 
Methods 111 
Full methods are provided in the online supplement.  112 
Study Participants  113 
The study was approved by the University of Cape Town Human Research Ethics Committee 114 
(REF 516/2011). All participants provided written informed consent. Cross-sectional study 115 
participants were retrospectively designated into four categories:  116 
1) HIV-uninfected patients without active TB (HIV-TB-) 117 
2) HIV-uninfected patients with a new diagnosis of active TB (HIV-TB+)  118 
3) ART naïve, HIV-infected patients without active TB (HIV+TB-)  119 
4) ART naïve, HIV-infected patients with a new diagnosis of active TB (HIV+TB+).  120 
Longitudinal study participants were ART naïve HIV-1-infected patients with a CD4 count 121 
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<200 cells/L and recently diagnosed TB. Longitudinal study visits occurred at TB diagnosis 122 
(TB0), ART initiation (ARV0), two (ARV2) and four (ARV4) weeks of ART and if new 123 
symptoms suggesting TB-IRIS occurred. TB-IRIS diagnosis was assigned retrospectively on 124 
expert case review, using consensus criteria (3).  125 
 126 
iNKT cell enumeration and characterisation 127 
PBMC were isolated over Ficoll and cryopreserved. Cells were rapidly thawed in warmed 128 
RPMI/10% FCS, before viability staining with Violet LIVE/DEAD© Fixable stain kit (VIVID, 129 
Invitrogen, Paisley, UK), then washed and re-suspended for incubation with either α-galcer-130 
loaded CD1d tetramer or control CD1d tetramer (Proimmune, Oxford, UK) for 30 minutes on 131 
ice, protected from light. Subsequently, cells were washed, stained with antibody mastermix 1 132 
(Supplementary Table S1) for 30 minutes at 4oC, washed and re-suspended in PBS, 1% Hi-133 
FCS and 2% paraformaldehyde, then incubated for 1 hour, washed and resuspended for 134 
acquisition.  135 
 136 
Data acquisition and analysis 137 
Data were acquired on an LSRFortessaTM (BD Biosciences, USA) and analysed using Flowjo 138 
software (Tree Star, Ashland, OR). iNKT cells were defined as CD3+ CD19- CD1d α-galcer 139 
tet+ Vβ11+ T cells. The gating strategy is shown in Figure 1A. iNKT cell frequency was 140 
calculated as a percentage of CD3+ CD19- live lymphocytes, with subtraction of the equivalent 141 
tetramer negative control proportion, and reported per million CD3+CD19- live lymphocytes. 142 
iNKT cell numbers were calculated by multiplying the iNKT cell frequency as a percentage of 143 
live lymphocytes with the total lymphocyte count per millilitre of peripheral blood (22).  144 
 145 
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Statistical analysis was performed using Prism 6 (GraphPad, UK) and STATA 14. Unadjusted 146 
non-parametric analyses were by two-tailed Fisher’s Exact or Mann–Whitney U, or for 147 
comparisons of more than two groups, by Kruskal-Wallis with Dunn’s multiple comparisons 148 
test. In the cross-sectional study, we used a multivariable linear regression model to investigate 149 
differences in iNKT cell frequency and in percentage iNKT cell CD4/CD8 expression by 150 
disease category. In the longitudinal study, a multivariable negative binomial model was fitted 151 
to examine associations of iNKT cell frequency and number with TB-IRIS status, and 152 
a multivariate linear regression model to estimate difference in CD4/CD8 cell subset 153 
percentages between TB IRIS and non-IRIS patients. 154 
 155 
Results 156 
PBMC samples were available from 101 patients (see Table 1). HIV+TB+ patients compared 157 
to HIV+TB- patients had lower total CD4 counts but similar CD4 percentages, and higher HIV-158 
1 viral loads. In HIV+TB+ compared to HIV-TB+, there were trends towards reduced cavitary 159 
(p=0.067), but increased miliary (p=0.051) and extra-pulmonary (p=0.054) TB presentation, 160 
indicating reduced destructive pulmonary pathology but more widely disseminated TB disease 161 
in HIV-infected patients (25).   162 
 163 
Circulating iNKT cells are depleted in HIV-1 infection and active TB 164 
In an unadjusted analysis, comparing iNKT cell frequency in HIV-1-infected and -uninfected 165 
patients, with and without active TB, we found that iNKT cell frequency was reduced in 166 
HIV+TB+ (p=0.001) and HIV+TB- (p=0.005) compared to HIV-TB- patients (Figure 1B and 167 
Table 2). Example plots are shown in Supplementary Figure S1. A similar pattern was observed 168 
in comparison of iNKT cell numbers (iNKT cells per ml, Figure 1C) and reduction in iNKT 169 
cells numbers was found in HIV-TB+ compared to HIV-TB- patients (p=0.044). Linear 170 
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regression comparing HIV-TB+, HIV+TB- and HIV+TB+ to HIV-TB- provided further 171 
evidence of association between reduced iNKT cell frequency in HIV+TB- (p=0.023) and 172 
HIV+TB+ (p=0.024) after adjustment for age and sex, but there was no evidence of a reduction 173 
in iNKT cell frequency in HIV-TB+ compared to HIV-TB- (p=0.301).  174 
 175 
CD4+ iNKT cell subsets are depleted in HIV-1 infection 176 
iNKT cells may exist as CD4+CD8-, CD4-CD8+, CD8+CD4+, or double negative (DN) 177 
subsets. CD4+ iNKT cells secrete both Th1 and Th2 cytokines and may be immunoregulatory, 178 
whilst CD8+ iNKT cells and DN iNKT cell subsets predominantly secrete Th1 cytokines and 179 
have increased cytotoxic functionality (26, 27). Unadjusted analyses showed that HIV-1 180 
infection was associated with lower CD4+ iNKT cell percentages (Figure 2A) and frequency 181 
(CD4+ iNKT cells per million CD3+ CD19- live lymphocytes, Figure 2B) in patients with 182 
(p=0.007) and without (p=0.005) active TB. Active TB did not clearly reduce CD4+ iNKT cell 183 
percentage, but was associated with reduced CD4+ iNKT cell frequency in HIV-uninfected 184 
patients (Figure 2B, p=0.016). In HIV-infected patients, total iNKT cell frequency did not 185 
correlate with peripheral blood CD4 T cell count, peripheral blood CD4 T cell percentage or 186 
HIV-1 viral load. However, CD4+ iNKT cell percentage was correlated with total peripheral 187 
blood CD4 T cell count (Figure 2C, r=0.456, p=0.001) and there was an inverse correlation 188 
with HIV-1 viral load (Figure 2D, r=-0.571, p<0.001), indicating most severe depletion of 189 
CD4+ iNKT cells occurred in advanced HIV infection.  190 
 191 
Next, we examined CD4 and CD8 co-expression on iNKT cells. In HIV-TB-, we found 192 
CD4+CD8- (Figure 2E) and DN iNKT cells (Figure 2F) to be the predominant iNKT cell 193 
subsets constituting a median of 42.1% and 43.7%  of the iNKT cell population respectively. 194 
However, compared to HIV-TB- patients, HIV-infected patients had reduced percentages of 195 
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CD4+CD8- iNKT cells, constituting a median of only 1.55% iNKT cells in HIV+TB+ 196 
(p<0.001). In HIV-infected patients, there was a trend towards an increased percentage of CD4-197 
CD8- iNKT cells (Figure 2F) and CD4-CD8+ iNKT cells (not shown), compared to HIV 198 
uninfected patients. To explore this further, we performed regression analysis comparing 199 
CD4/CD8 iNKT cell percentages in each group to HIV-TB-, adjusting for age and sex 200 
(Supplementary Table S2). This analysis showed evidence of reduced CD4+CD8- iNKT cells 201 
in HIV+TB- and HIV+TB+ compared to HIV-TB- (p<0.001 for both) and increased CD4-202 
CD8- percentage in HIV+TB- (p=0.010). CD4-CD8+ cells were increased in HIV+TB- 203 
(p=0.037) and HIV+TB+ (p=0.016) compared to HIV-TB-. For CD4/CD8 subset iNKT cell 204 
frequencies, see Supplementary Figure S2. 205 
 206 
iNKT cells in HIV-associated TB are pro-inflammatory with a cytotoxic phenotype 207 
There was high iNKT cell surface expression of the maturation marker, CD161, CD95 and 208 
PD1 in HIV+TB+, but not more than in the control groups (data not shown). We investigated 209 
iNKT cell degranulation by measuring CD107a surface expression (28). CD107a+ iNKT cells 210 
were increased in HIV+TB+ patients, compared to HIV+TB- patients, suggesting increased 211 
cytotoxic degranulation (Figure 3A), but this phenotype was not observed in all HIV+TB+ 212 
patients. To explore this further, we investigated association between CD107a+ iNKT cell 213 
positivity and TB disease phenotype in HIV+TB+. We found  significantly increased CD107a+ 214 
iNKT cell percentage in HIV+TB+ patients with clinical features of extrapulmonary TB 215 
compared to those without, consistent with the hypothesis that disseminated Mtb might lead to 216 
peripheral blood iNKT cell degranulation (Figure 3B).  217 
 218 
 219 
 9 
In summary, we found that HIV infection was associated with iNKT cell depletion and CD4+ 220 
iNKT cell subsets were most significantly depleted in advanced HIV. Active TB was associated 221 
with a modest reduction in iNKT cell number in HIV-uninfected patients, but did not clearly 222 
reduce iNKT cell frequency. The immunoregulatory CD4+CD8- iNKT cell subset, the 223 
predominant subset in the healthy repertoire, was depleted in HIV-infected patients with and 224 
without active TB. CD4-CD8+ and DN iNKT cells were the dominant iNKT cell subsets in 225 
HIV-infected patients. There were increased CD107a+ iNKT cell percentages in HIV-infected 226 
patients with active TB, indicating a cytotoxic phenotype, which was associated with extra-227 
pulmonary TB.  228 
 229 
iNKT cell frequency is increased in TB-IRIS patients 230 
Next, in a longitudinal study, we evaluated iNKT cells in patients with advanced HIV and 231 
recently diagnosed TB, who commenced TB treatment and then ART, and were at risk of 232 
paradoxical TB-IRIS. Fifty-seven participants were enrolled. Clinical features of this cohort 233 
have previously been reported (25). Paradoxical TB-IRIS was diagnosed in 29 (59.2%) 234 
patients. Participants were included if PBMC were available at least one study timepoint (TB0, 235 
ARV0, ARV2 and ARV4) and there was follow up to ARV12. One participant was excluded 236 
as no PBMC samples were available, another as they were an elite controller and therefore 237 
likely to be immunologically distinct, and a third due to hepatotoxicity on TB treatment 238 
resulting in a significant delay to ART initiation. The subsequent analysis reports findings from 239 
29 TB-IRIS patients and 17 non-IRIS controls. Patient demographics and TB diagnosis are 240 
provided in Table 3 and were not significantly different comparing TB-IRIS with non-IRIS 241 
patients. Between ARV0 and ARV4, peripheral blood CD4 T cell counts increased (p<0.001) 242 
from median 101 cells/l to 206 cells/l in TB-IRIS patients and from 99 cells/l to 175 cells/l 243 
in non-IRIS patients.  244 
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 245 
First, we enumerated iNKT cells. We found an elevated iNKT cell frequency in TB-IRIS 246 
compared to non-IRIS patients (Figure 4A). At ARV2, the most frequent time of TB-IRIS 247 
presentation, the median iNKT cell frequency per million CD3+CD19- live lymphocytes in 248 
TB-IRIS was 992 (IQR, 166-5682) compared to 100  (IQR 24.5-440) in non-IRIS patients 249 
(p=0.025 in unadjusted analysis). Multivariable modelling including data from timepoints 250 
ARV0, ARV2 and ARV4 demonstrated a significant association between TB-IRIS and 251 
increased iNKT cell frequency, adjusted for age and sex (p=0.022, Supplementary Table S3), 252 
but no increase in iNKT cell frequency over time and the association did not differ with total 253 
peripheral blood CD4 T cell count, nor HIV viral load. A similar trend was found for iNKT 254 
cell numbers in the adjusted logistic regression analysis (p=0.062, Supplementary Figure S3). 255 
 256 
iNKT cell function and phenotype in TB-IRIS  257 
Next, we examined CD4/CD8 iNKT cell subsets in the longitudinal study. CD4+ iNKT cell 258 
percentage and frequency were low, both in TB-IRIS and non-IRIS patients and did not 259 
increase in the first four weeks of ART, despite an increased peripheral blood CD4 T cell count. 260 
CD4+CD8- iNKT cell percentage was significantly lower in TB-IRIS patients than non-IRIS 261 
patients, (p=0.015 by multivariate linear regression modelling, Figure 4B). Supplementary 262 
Figure S4 shows CD4/CD8 subset frequency demonstrating a predominance of DN and CD4-263 
CD8+ iNKT cells in TB-IRIS compared to non-IRIS patients, at ARV2 (p=0.029 and p=0.036 264 
respectively).   265 
 266 
In both TB-IRIS and non-IRIS patients, CD161+ iNKT cell and CD107a+ iNKT cell 267 
percentages were dynamic (Supplementary Figure 5 A-B). CD95 cell surface expression, 268 
indicative of cytotoxicity,  and PD1+ iNKT cell percentages were high both in TB-IRIS and 269 
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non-IRIS patients whilst CD40L+ iNKT cell percentages were relatively low, possibly 270 
indicating iNKT cell exhaustion (Supplementary Figure S5 C-E) (22, 29). In TB-IRIS, CD161+ 271 
iNKT cell percentages decreased between ARV0 and ARV2, suggesting a loss of mature iNKT 272 
cells, whereas in non-IRIS patients, iNKT cell CD161 positivity was similar (Figure 5A). In 273 
TB-IRIS patients, CD107a+ iNKT cells increased between ARV0 and ARV2 relative to non-274 
IRIS patients, suggesting degranulation occurred at the time of IRIS symptom onset (Figure 275 
5B). CD107a+ iNKT cell frequency was increased in TB-IRIS compared to non-IRIS patients 276 
at ARV2 (Figure 5C).  277 
 278 
In summary, patients with advanced HIV and active TB had low circulating iNKT cell 279 
frequency pre-ART initiation, but iNKT cell populations were skewed towards pro-280 
inflammatory, cytotoxic subsets. Higher iNKT cell frequency was associated with TB-IRIS 281 
following ART initiation and iNKT cells in TB-IRIS patients were CD4+CD8- subset deplete, 282 
with increased DN and CD4-CD8+ iNKT cell frequency at the time of TB-IRIS onset. 283 
Increased CD107a+ iNKT cell subsets in TB-IRIS patients also at ARV2 suggested increased 284 
iNKT cell degranulation occurring at the time of TB-IRIS presentation.  285 
 286 
Discussion 287 
In this study, we demonstrated low iNKT cell frequency in ART-naïve patients with advanced 288 
HIV infection, with a paucity of CD4+ iNKT cells, and relatively increased proportions of 289 
CD4-CD8- iNKT cells, representing a shift from CD4+ subsets found in HIV-uninfected 290 
patients. Decreased iNKT cell numbers and CD4+ iNKT cell frequency were associated with 291 
active TB in patients without HIV infection, but this finding was not consistent in HIV-infected 292 
patients. In HIV-infected patients with active TB, increased degranulation of iNKT cells was 293 
found. Despite low iNKT cell frequencies in these patients, there were relatively increased 294 
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iNKT cells in patients who went on to develop TB-IRIS compared to those who did not and 295 
these were predominantly DN or CD4-CD8+ iNKT cells. There was no significant recovery in 296 
peripheral blood CD4+ iNKT cells in the first four weeks of ART, despite increased peripheral 297 
blood CD4 count (25).  298 
 299 
Our findings are consistent with prior human studies measuring iNKT cells in HIV infection, 300 
which report reduced iNKT cell frequency in HIV-infected patients (23, 30, 31). A previous 301 
study demonstrated that in vitro HIV-1 infection directly infects and selectively depletes CD4+ 302 
iNKT cells. Activated iNKT cells were more susceptible to HIV-1 infection than conventional 303 
CD4 T cells.  (32). In HIV-leprosy co-infection, iNKT cell populations were found to be 304 
reduced more profoundly than in leprosy or HIV infection alone (33). iNKT cell activation due 305 
to mycobacterial infection might exacerbate iNKT cell depletion in HIV-1 infected patients. 306 
Although we found the lowest iNKT cell frequency and numbers in patients with HIV-1 307 
infection and active TB, active TB did not clearly have an additive effect of iNKT cell depletion 308 
in HIV-infected patients. 309 
 310 
There are a number of potential mechanisms by which iNKT cells may contribute to 311 
immunopathology in TB-IRIS. They may directly recognise foreign or self lipid antigens 312 
presented via CD1d, or become activated by local cytokine networks (26). Once activated 313 
iNKT cells may rapidly secrete proinflammatory cytokines and chemokines promoting CD4 T 314 
cell expansion, activation and neutrophil infiltration, features of TB-IRIS we have previously 315 
shown, in addition to causing cell death (5, 6, 9, 10, 26, 34). Ultimately, this cascade may lead 316 
to MMP activation and tissue destruction, in turn propagating proinflammatory cytokine 317 
secretion in the vicious cycle of hyperinflammation that is the hallmark of TB-IRIS (7, 25).  318 
 319 
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iNKT cell quantification using α-galcer-loaded CD1d-loaded tetramers, is recognised as a 320 
stringent method of iNKT cell quantification (35, 36). However, we cannot extrapolate our 321 
findings beyond the limitations of this methodology, which may be affected by TCR 322 
downregulation on activation, nor beyond peripheral blood into tissue compartments (35). It is 323 
possible that increased circulating iNKT cells in TB-IRIS patients represents failure of 324 
migration to tissues. We found evidence of increased iNKT cell degranulation in extra-325 
pulmonary TB, compared to pulmonary TB, raising the possibility that more abundant, 326 
disseminated Mtb antigen may drive iNKT cell degranulation in HIV-associated TB and 327 
increased iNKT cell cytotoxicity in TB-IRIS patients (24).   328 
 329 
As a rare T cell subset, iNKT cells have formerly been difficult to study and iNKT cell function 330 
in infection is a relatively understudied area. However, in the field of oncology, adjuvants to 331 
boost iNKT cell cytotoxicity have been the focus of translational research and have entered 332 
early phase clinical trials (37, 38). Our study suggests that boosting iNKT cell cytotoxicity 333 
would not be an appropriate strategy in HIV-associated TB. However, an improved 334 
understanding of the role of iNKT cells in TB immunopathology could identify novel 335 
therapeutic targets. As human and mouse iNKT cell physiology differ, further human clinical 336 
and cellular studies are required, including study of iNKT cells in tissue compartments.  337 
 338 
Conclusion 339 
This study supports a role for iNKT cells in innate immune dysfunction in paradoxical TB-340 
IRIS. We have shown profound CD4+ iNKT cell subset depletion in advanced HIV-1 infection 341 
and a lesser effect of active TB in HIV-uninfected patients. In patients with advanced HIV and 342 
a new diagnosis of active TB, iNKT cell populations were skewed towards a proinflammatory, 343 
cytotoxic phenotype. Patients who developed TB-IRIS had increased iNKT cells compared to 344 
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non-IRIS patients and iNKT cell degranulation occurred at the time of IRIS, potentially 345 
contributing to immunopathology.   346 
  347 
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Figure Legends 486 
Figure 1 Reduced iNKT cells in HIV-1 infection and active TB  487 
iNKT cells were enumerated by flow cytometry using ⍺-galcer loaded CD1d tetramers. Each 488 
sample was stained in parallel with a control tetramer (without ⍺-galcer) to identify non-489 
specific tetramer binding for subtraction. The gating strategy shown in (A) demonstrates an 490 
iNKT cell frequency of 0.77%, with no control tetramer binding, equivalent to 7700 cells per 491 
million CD3+CD19- live lymphocytes. Decreased iNKT cell frequency (B) was found in HIV-492 
infected patients with active TB (HIV+TB+) and without active TB (HIV+TB-), compared to 493 
HIV-uninfected patients without active TB (HIV-TB-). Similarly, in HIV-infected patients with 494 
and without active TB, decreased iNKT cell numbers (cells per millilitre peripheral blood (C)) 495 
were found compared to HIV-uninfected patients without active TB. Additionally, in HIV-496 
uninfected patients with active TB (HIV-TB+), iNKT cell numbers were reduced compared to 497 
HIV-uninfected patients without TB.  Analysis was by Kruskal Wallis with Dunn’s multiple 498 
comparison’s test to calculate adjusted p values: *p<0.05; **p<0.01; ***p<0.001. In (B) and 499 
(C), zero values were replaced by one for representation on a log scale. 500 
 501 
Figure 2 CD4+ iNKT cell subset depletion in HIV-1-associated TB  502 
HIV-infected patients, most significantly those with active TB, had depleted CD4+ iNKT cells 503 
as measured by percentage of total iNKT cell count (A) and frequency per million CD3+ CD19- 504 
live lymphocytes (B).  In HIV-infected patients, peripheral blood CD4 T cell count positively 505 
correlated with CD4+ iNKT cell percentage (C). HIV-1 viral load negatively correlated with 506 
CD4+ iNKT cell percentage (D).  In HIV-uninfected patients without active TB, iNKT cells 507 
were mostly either CD4+ CD8- or double negative (CD4-CD8-), whilst in HIV-infected 508 
patients CD4+ CD8- iNKT cells were depleted and double negative iNKT cells were the 509 
predominant subset (E, F). Analysis was by Kruskal Wallis with Dunn’s multiple comparisons 510 
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test to calculate multiplicity-adjusted p values: * p<0.05; ** p<0.01; *** p<0.001 or by 511 
Spearman’s correlation (C, D). 512 
 513 
Figure 3 iNKT cell cytotoxicity in HIV-associated TB  514 
In HIV-associated TB, there were increased percentages of CD107a+ iNKT cells, suggestive 515 
of cytotoxic degranulation (A). In HIV-infected patients with clinical features of extra-516 
pulmonary TB (EPTB), there were increased CD107a+ iNKT cell percentages compared to 517 
HIV-infected patients with pulmonary TB (B). Analysis was by Kruskal Wallis with Dunn’s 518 
multiple comparisons test to calculate multiplicity-adjusted p values or by Mann-Whitney U in 519 
(D): * p<0.05.  520 
 521 
Figure 4 iNKT cells are elevated in TB-IRIS patients and are CD4+CD8- subset 522 
deplete 523 
iNKT cells were enumerated longitudinally by flow cytometry using ⍺-galcer loaded CD1d 524 
tetramers, in a cohort of 46 HIV-1-infected patients with active TB. Samples were collected 525 
around the time of TB diagnosis (TB0), at anti-retroviral therapy initiation (ARV0, a median 526 
of 17.5 days post TB treatment initiation) and at two weeks (ARV2) and four weeks (ARV4) 527 
post-ART initiation although not all patients contributed data to the first timepoint as patients 528 
who had taken more than four doses of TB treatment at  enrolment contributed data from ARV0, 529 
resulting in fewer data points at TB0. TB-IRIS presentation was typically at ARV2. Increased 530 
iNKT cell frequency (A) was observed in TB-IRIS patients compared to non-IRIS controls. 531 
CD4+CD8- iNKT cell percentages were reduced in TB-IRIS patients (B). Statistical analysis 532 
was by multivariable negative binomial modelling to examine associations of iNKT cell 533 
frequency and number with TB-IRIS status and by multivariate linear regression modelling to 534 
estimate difference in CD4/CD8 cell subset percentages between TB IRIS and non-IRIS 535 
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patients, including data from all timepoints to derive p values which are reported on the 536 
corresponding figure. In (A), zero values were replaced by one for representation on a log scale.  537 
 538 
Figure 5 iNKT cell cytotoxicity associated with TB-IRIS  539 
iNKT cells were characterised longitudinally by flow cytometric analysis for surface markers 540 
CD161 and CD107a, in TB-IRIS patients and non-IRIS patients . Between ARV0 and ARV2, 541 
CD161+ iNKT cells there was a reduction in CD161+ iNKT cell percentage in TB-IRIS 542 
compared to non-IRIS patients (A), whereas CD107a+ iNKT cell percentage increased in TB-543 
IRIS patients between ARV0 and ARV2, compared to non-IRIS patients (B). CD107a+ iNKT 544 
cell frequency (cells per million CD3+CD19- live lymphocytes) was increased in TB-IRIS 545 
patients compared to non-IRIS controls at ARV2, the most common time of TB-IRIS 546 
presentation (C). Mann-Whitney U analysis for TB-IRIS vs non-IRIS: * p<0.05; **p<0.01. 547 
  548 
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Table 1 Demographic and clinical features of the cross-sectional study participants 549 
 550 
  HIV-TB- HIV-TB+ HIV+TB- HIV+TB+ p value 
 
n 
32 20 26 23   
Female, n (%) 14 (43.8) 7 (35.0) 15 (57.7) 9 (39.1) >0.100a 
Smoking status: 
 current or ex,, n (%) 
17 (53.1) 10 (50.0) 9 (34.6) 9 (39.1) >0.100a 
Age, median years (IQR) 29.0 (23.3-38.8) 38.0 (30.0-42.8) 32.5 (28.5-35.3) 31.0 (28.0-40.0) 0.059b 
CD4 T cell count,  
median cells/ml (IQR) 
N/A N/A 349 (204-483) 187 (104-386) 0.041 
CD4 T cell percentage, 
median (IQR) 
N/A N/A 17.8 (12.0-22.3) 13.7 (9.22-26.3) 0.901 
HIV viral load,  
median copies/ml (IQR) 
N/A N/A 25735 (6807-
92169) 
296196 (13540-
503097) 
0.031 
      
Symptomatic, n (%) 16 (50.0) 20 (100) 10 (38.5) 23 (100)  
Duration of symptoms, 
median days (IQR) 
14.0 (4.00-150) 28.0 (14.0-30.0) 60.0 (11.3-82.5) 30.0 (21.0-30.5) 0.595C 
Miliary TB, n (%) 0 (0) 0 (0) 0 (0) 5 (21.7) 0.051d 
Extrapulmonary TB, n (%) N/A 3 (15.0) N/A 10 (43.5) 0.054d 
Smear positive TB, n (%) 0 (0) 13 (65.0) 0 (0) 8 (34.8) 0.069d 
Culture positive TB, n (%) 0 (0) 10 (50.0) (0) 18 (78.3) 0.064d 
Clinical diagnosis TB, n (%) 0 (0) 3 (15.0) 0 (0) 2 (8.70) 0.650 
Cavitary disease on CXR,  
n (%) 
0 (0) 14 (70.0) 0 (0) 9 (39.1) 0.067d 
 551 
afor comparison between each group by Fisher’s Exact test 552 
bfor comparison of all groups by Kruskal-Wallis test, Dunn’s multiple comparisons test for a difference between HIV-TB- and HIV-553 
TB+ (p=0.033) 554 
cfor comparison of all groups by Kruskal-Wallis test 555 
dfor comparison between HIV-TB+ and HIV+TB+ by Fisher’s Exact test 556 
  557 
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Table 2 iNKT cell enumeration in cross-sectional study participants by diagnosis 558 
 559 
Patient category Dunn’s multiple comparisons test 
HIV- TB- HIV- TB+ HIV+TB- HIV+TB+ HIV- TB- vs. 
HIV- TB+ 
HIV- TB- vs. 
HIV+TB- 
HIV- TB- vs. 
HIV+TB+ 
HIV+TB- vs. 
HIV+TB+ 
HIV- TB+ vs. 
HIV+TB+ 
 
iNKT cell frequency, median per million CD3+CD19- live lymphocytes (IQR) 
 
1700  
(1125, 
2600) 
735  
(253, 
1800) 
375  
(198, 
1775) 
280  
(62.7, 
1300) 
0.149 0.005 0.001 >0.999 0.731 
 
iNKT cell number, median cells per ml blood (IQR) 
 
 
282628 
(151100, 
487870) 
88580 
(29600, 
203771) 
44965 
(19635, 
219669) 
24439 
(3789, 
119449) 
0.044 0.002 <0.001 0.432 0.161 
 
CD4+ iNKT cells, median percentage (IQR) 
 
 
44.5  
(27.9, 61.1) 
38.9  
(16.3, 
67.1) 
13.67 
(2.77, 
39.2) 
3.15  
(0, 39.6) 
>0.999 0.005 <0.001 >0.999 0.007 
 
CD4+ iNKT cell frequency, median per million CD3+ CD19- live lymphocytes (IQR) 
 
 
712  
(451, 1043) 
202  
(78.8, 601) 
100  
(11.5, 236) 
18.9  
(0, 148) 
0.016 <0.001 <0.001 >0.999 0.013 
   560 
 27 
Table 3 Demographic and clinical features of participants in longitudinal study at enrolment 561 
 562 
 TB-IRIS non-IRIS p value 
n (%) 29 (63.0) 17 (37.0)  
Female, n (%) 14 (48.3) 10 (58.8) 0.552 
Smoking status: current or ex-, n (%) 9 (31.0) 3 (17.5) 0.489 
Age, median years (IQR) 35.0 (29.5-42.0) 35.0 (30.5-43.0) 0.924 
CD4 T cell count, median cells/l 
 (IQR) 
89.0  
(64.0-141.5) 
82.0  
(69.5-145.5) 
0.987 
HIV-1 viral load, median copies/ml  
(IQR) 
621075  
(207018-1185455) 
520295  
(126925-1029554) 
0.343 
Extrapulmonary TB, n (%) 21 (72.4) 12 (70.6) 1.00 
Miliary TB, n (%) 5 (17.2) 1 (5.88) 0.390 
Smear positive TB, n (%) 14 (48.3) 5 (29.4) 0.235 
Culture positive TB, n (%) 21 (72.4) 11 (64.7) 0.742 
Clinical diagnosis TB, n (%) 2 (6.90) 4 (23.5) 0.174 
ART initiation, days post TB treatment initiation 
(IQR) 
15  
(14-28) 
21  
(14-41) 
0.186 
IRIS symptom onset, median days post-ART 
initiation (IQR) 
6  
(4-10) 
N/A  
IRIS presentation, median days post-ART initiation 
(IQR) 
14  
(9-15) 
N/A  
INSHIa criteria for paradoxical TB-IRIS  fulfilled, n 
(%) 
25 (86.2) 0 (0)  
 563 
aInternational Network for the Study of HIV-associated IRIS 564 
 565 
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Materials and Methods 
Study Participants and clinical assessment 
 The study was approved by the University of Cape Town Human Research Ethics Committee 
(REF 516/2011) and conducted in accordance with the Declaration of Helsinki. Cross-sectional 
study participants were recruited in an outpatient clinic in Khayelitsha, South Africa and were 
either healthy volunteers, patients with symptoms requiring assessment, or recently 
diagnosed TB patients.  HIV-infected patients were ART naive at enrolment. Cross-sectional 
study participants who were on anti-tuberculosis therapy were required to have had less than 
3 doses prior to study samples being collected. Once enrolled, cross-sectional study 
participants were provided appropriate follow up by the research team for study clinical 
results and were then followed up routinely by clinic staff, unless also eligible for the 
longitudinal study.  
 
Cross-sectional study participants were retrospectively designated into four categories:  
1) HIV-uninfected patients without active TB (HIV-TB-) 
2) HIV-uninfected patients with a new diagnosis of active TB (HIV-TB+)  
3) ART naïve, HIV-infected patients without active TB (HIV+TB-)  
4) ART naïve, HIV-infected patients with a new diagnosis of active TB (HIV+TB+).  
 
Active TB was diagnosed on the basis of smear or culture positivity, or in cases of smear-
negative TB according to international guidelines [1, 2]. This required suggestive symptoms 
 2 
and at least one of: 
a) Sputum smear positive for acid fast bacilli on microscopy (Smear positive) 
b) Sputum Gene Xpert-RIF (Cepheid, Sunnyvale, CA) positive for Mycobacterium 
tuberculosis (Mtb)  
c) Sputum culture positive for Mtb (Culture-confirmed) 
d) Clinical features highly suggestive of TB such as diagnostic features on chest 
radiograph or other imaging modality and a decision to start TB treatment by the 
treating clinician (Clinical diagnosis) 
Cross-sectional study participants who had symptoms but did not meet the criteria for TB 
diagnosis were designated controls if there was a low clinical suspicion for active TB and they 
had at least one induced sputum smear negative for acid fast bacilli and one induced sputum 
culture that was negative for Mtb. These patients were not started on anti-tuberculosis 
therapy.  All HIV-infected patients who were designated non-TB controls also had at least one 
induced sputum smear negative for acid fast bacilli and one induced sputum culture that was 
negative for Mtb. HIV-infected active TB patients in the cross-sectional study who met 
eligibility criteria for the longitudinal study were co-enrolled, or if eligibility became apparent 
after enrolment, were invited to subsequently participate in the longitudinal study. 
 
Longitudinal study participants were ART naïve HIV-infected patients with a low CD4 count 
(<200 cells/mm3) and a recent diagnosis of active TB. Following anti-tuberculosis therapy 
initiation and enrolment into the longitudinal study (study visit TB0) patients received 
counselling for ART initiation. Anti-tuberculosis therapy and ART followed national guidelines 
[3, 4]. First-line ART at the time of the study was principally tenofovir, lamivudine, and 
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efavirenz. ART was initiated typically two weeks after anti-tuberculosis therapy (study visit 
ARV0) and patients attended further scheduled study visits at two weeks post-ART initiation 
(ARV2, Day 14 +/- 72 hours) and four weeks post-ART initiation (ARV4, Day 28 +/-72 hours) 
for clinical assessment and sampling. Patients who had taken more than four doses of TB 
treatment at enrolment contributed samples from ARV0. 
 
Patients were requested to attend for assessment if any new symptoms or clinical 
deterioration occurred (study interim assessment) and were followed up to twelve weeks 
post-ART initiation. Clinical research staff telephoned participants regularly to reinforce this, 
to remind patients about scheduled visits and to investigate non-attendance. If a case of TB-
IRIS was suspected, study samples were collected as at a scheduled visit, in addition to 
clinically indicated diagnostic tests. Where possible, when patients were hospitalized at the 
time of a study visit, they were visited by the study team for data and sample collection. 
Retrospective designation into one of three longitudinal study categories (paradoxical TB-IRIS 
(INSHI IRIS), probable paradoxical TB-IRIS not meeting INSHI criteria (IRIS non-INSHI), and no 
paradoxical TB-IRIS (non-IRIS)) followed the results of all relevant investigations and clinical 
follow up, and was made on case review by a consensus panel (comprising the study clinician 
NFW, and two clinical specialists: GM, RJW). Designation as TB-IRIS included both INSHI-IRIS 
and non-INSHI IRIS.  
 
In both cross-sectional and longitudinal studies, demographic information was recorded at 
enrolment, including gender and smoking status. At each study visit, symptoms and clinical 
examination, full blood count, albumin, C-reactive protein (CRP) and chest radiograph were 
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performed, plus additional investigations if clinically indicated. Induced sputum and venous 
blood were collected (see below) at each visit for microbiological and laboratory analysis.  
 
Venous blood for PBMC isolation was collected in sodium heparin vacutainers, transported at 
room temperature to UCT, and processed within four hours of collection. PBMC were isolated 
by layering over Ficoll and cryopreserved in heat-inactivated fetal calf serum (FCS) with 10% 
dimethyl sulfoxide (DMSO) until used in batches.  
 
Additional venous blood sample analysis was performed by the National Health Laboratory 
Service (NHLS), including full blood count and differential measured using a Siemens Advia 
2120I (Siemens, Surrey, UK), albumin and C-reactive protein (CRP) quantification on a Roche 
Modular (F. Hoffman-La Roche Ltd) and for HIV-infected patients, CD4 count measured on a 
Beckman Coulter FC500MP (Beckmann Coulter, Inc, Buckinghamshire, UK) and HIV-1 viral 
load measured on an Abbott M2000 (Abbott Analytical Limited, London, UK). Induced sputum 
was collected for microscopy and mycobacterial culture.  
 
CD1d Tetramer staining 
Cryopreserved PBMC were rapidly thawed in warmed RPMI/10% FCS and washed. All wash 
steps consisted of centrifugation at 1500 rpm for 5 minutes, discarding of supernatant and 
disruption of the cell pellet by vortex. PBMC were counted using a Bio-rad TC20TM automated 
cell counter and viability was ascertained by trypan blue exclusion. For iNKT cell enumeration, 
one million cells per tube were transferred into two labelled fluorescence activated cell 
 5 
sorting (FACS) tubes per patient: one for α-galcer-loaded CD1d tetramer and one for CD1d 
(control) tetramer staining for each sample.  Cells were washed in PBS and resuspended for 
viability staining with Violet LIVE/DEAD© Fixable stain kit (VIVID, Invitrogen, Paisley, UK) 
(1:1000 dilution, 200μl per tube) and incubated for 30 minutes at 4oC in the dark. They were 
then washed in PBS and resuspended in 30μl cold PBS prior to tetramer staining with α-galcer-
loaded CD1d tetramer (tet+) or control CD1d tetramer (tet-cont) (Proimmune, Oxford, UK), 
added at 0.5ul per tube and then incubated for 30 minutes on ice.   Tet+ and tet-cont-stained 
cells were protected from light at all times.  
 
Characterisation by cell surface marker expression 
Following tetramer staining, cells for surface marker characterisation were stained with an 
antibody mastermix containing CD3, CD19, CD4, CD8, CD107a, CD95, CD161, CD40L, PD1, and 
Vβ11 for 30 minutes at 4oC (see Supplementary Table S1). They were then washed and re-
suspended in PBS, 1% Hi-FCS, 2% paraformaldehyde for 1 hour. After a further wash, cells 
were re-suspended in 300μl wash buffer and acquired on an LSR Fortessa (BD Biosciences) 
within 24 hours of staining. Single fluorochrome-stained positive and negative control 
compensation beads were acquired for each experiment to enable fluorescence 
compensation. Data were analysed using Flowjo software (Tree Star, Ashland, OR).  
 
 iNKT cell frequency was calculated as a percentage of CD3+ CD19- live lymphocytes, with 
subtraction of the equivalent tet-cont proportion, and reported per million CD3+CD19- live 
lymphocytes. Negative values were reassigned zero for analysis. Zero values were assigned 1 
 6 
if graphically represented on a log scale. Absolute iNKT cell numbers were calculated by 
multiplying the iNKT cell count, as a percentage of live lymphocytes, with the total lymphocyte 
count per milliliter of peripheral blood, as previously reported [5]. Phenotypic characteristics 
of iNKT cells are reported as the iNKT cell percentage expressing cell surface markers (CD4, 
CD8, CD107a, CD95, CD161, CD40L, PD1). This proportion was multiplied by the total iNKT cell 
frequency to give the iNKT cell subset frequency.  
 
Statistical analysis 
Flow cytometry data was analysed using Flowjo software (Treestar, USA). Gating was 
determined by comparison to samples stained by the control tetramer or fluorescence-
minus-one controls. Statistical analysis was performed using Prism 6 (GraphPad, UK) and 
STATA version 14. Unadjusted non-parametric analyses were by two-tailed Fisher’s Exact or 
Mann–Whitney U, or for comparisons of more than two groups, by Kruskal-Wallis with Dunn’s 
multiple comparisons test. Comparison of total CD4 count changes over time in the 
longitudinal study was by two-way repeated measures ANOVA. In the cross-sectional study, 
we used a multivariable linear regression model to investigate differences in  iNKT cell 
frequency and percentage CD4/CD8 expression by disease category. In the longitudinal study, 
a multivariable negative binomial model was fitted to examine the association of iNKT 
frequency with TB-IRIS status and a multivariate linear regression model was used to estimate 
the difference in CD4/CD8 cell subset percentages between TB IRIS and non-IRIS patients. 
Data from scheduled visits, ARV0, ARV2 and ARV4 was included in this analysis and ARV0 was 
used as the baseline timepoint. 
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Supplementary Figure Legends 
Supplementary Figure S1 iNKT cell enumeration in cross-sectional study participants 
iNKT cells were enumerated using α-galcer-loaded CD1d tetramers and control CD1d 
tetramers (no α-galcer). Gating on CD3+ CD19- live lymphocytes generated the plots shown. 
For each participant, peripheral blood mononuclear cells were stained using α-galcer-loaded 
CD1d tetramers (column A) in parallel with a control tetramer (column B).  iNKT cells (shown 
in Q2, column A) were defined as CD3+ CD19- CD1d α-galcer tet+ Vβ11+ T cells and 
enumerated by subtraction of non-specific tetramer staining in the equivalent control gate 
(Q2 column B). Representative plots are shown for each of the four patient categories in the 
cross-sectional study: HIV-uninfected patients without active TB (HIV-TB-); HIV-uninfected 
patients with active TB (HIV-TB+); HIV-1-infected patients without active TB (HIV+TB-); HIV-1-
infected patients with active TB (HIV+TB+).  
 
Supplementary Figure S2 CD4 and CD8 iNKT cell subset frequency in cross-sectional study 
patients 
CD4+CD8- iNKT cell subset frequency (cells per million CD3+CD19- live lymphocytes) was 
reduced in HIV infection and in active TB in HIV-uninfected patients (A). There was reduced 
CD4-CD8- iNKT cell frequency in HIV-infected patients with active TB compared to HIV-
uninfected patients without active TB (B). There was no difference in iNKT cell frequency of 
CD-CD8+ (C) or CD4+ CD8+ (D) iNKT cell frequency between HIV-infected and uninfected 
patients, with and without active TB. Analysis was by Kruskal Wallis with Dunn’s multiple 
comparison’s test to calculate multiplicity adjusted p values: *p<0.05; **p<0.01;  ***p<0.001.  
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Supplementary Figure S3 iNKT cell numbers in longitudinal study patients 
iNKT cells were enumerated by flow cytometry using ⍺-galcer loaded CD1d tetramers, in a 
cohort of 46 HIV-1-infected patients with active TB. Following TB diagnosis (TB0), TB treatment 
was initiated. Anti-retroviral therapy was initiated at ARV0, a median of 17.5 days post TB 
treatment initiation. Patients who had taken more than four doses of TB treatment at 
enrolment contributed data from ARV0, resulting in fewer data points at TB0. Additional study 
visits occurred at two (ARV2) and four (ARV4) weeks post-ART initiation. TB-IRIS presentation 
was typically at ARV2.  iNKT cell numbers were calculated by multiplying the iNKT cell count, 
as a percentage of live lymphocytes quantified by flow cytometry, with the total lymphocyte 
count per millilitre of peripheral blood as recorded on the full blood count. There was a trend 
towards increased iNKT cell numbers in TB-IRIS patients compared to non-IRIS controls in the 
age and sex-adjusted multivariate model (p=0.062). Zero values were replaced by one for 
representation on a log scale.  
 
Supplementary Figure S4 CD4 negative iNKT cell subsets predominate in TB-IRIS and non-
IRIS patients 
CD4-CD8- and CD4-CD8+ iNKT cell subset percentage (A, B) and iNKT cell frequency per million 
CD3+ CD19- live lymphocytes (C, D) are shown. CD4-CD8- iNKT cells were the most abdundant 
as a percentage of total iNKT cells (A), followed by CD4-CD8+ iNKT cells (B) in both TB-IRIS and 
non-IRIS patients. However, in TB-IRIS patients CD4-CD8- (C) and CD4-CD8+ (D) iNKT cell 
frequency was increased compared to non-IRIS patients at ARV2, the usual time of IRIS 
presentation. CD4+CD8+ iNKT cells were infrequent (data not shown). Zero values were 
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replaced by 0.1 for representation on a log scale. Analysis was by Mann Whitney-U comparing 
TB-IRIS with non-IRIS at each timepoint: *p<0.05.  
 
Supplementary Figure S5 iNKT cell phenotype in HIV-associated TB 
iNKT cells where characterized by proportional surface expression of CD161, CD107a, CD95, 
PD1 and CD40L, indicating maturation, degranulation, cytotoxicity, anergy and activation, 
respectively. CD161+ (A) and CD107a+ (B) iNKT cell proportions were dynamic. CD95+ iNKT 
cell proportions were very high in both TB-IRIS and non-IRIS patients (C). PD1+ iNKT cell 
proportions were relatively high (E) whereas CD40L+ iNKT cell proportions were relatively 
low, possibly indicating an exhausted state (F). Individual patient data are shown and 
consecutive visits are joined by a line. Routine study visits were at ARV0 (anti-retroviral 
therapy initiation), ARV2 and ARV4 (two and four weeks post-ART initiation). Unscheduled 
study visits indicating new symptoms were at ARV1 and ARV3 (one and three weeks post-
ART initiation).  
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Supplementary Tables 
 
Supplementary Table S1 Flow cytometry panel for iNKT cell enumeration and phenotype, 
comprising LIVE/DEAD© Fixable stain (VIVID), either α-galcer-loaded CD1d tetramer or control 
CD1d tetramer and antibodies for cell surface markers (surface antibody mastermix 1). 
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Supplementary Table S2 Multivariable linear regression model of CD4/CD8 percentage 
expression on iNKT cells in the cross-sectional cohort by clinical category in comparison to 
HIV-uninfected controls without active TB (HIV-TB-), adjusted for age and sex. 
 
  Coefficient 95% CI p value 
CD4-CD8+     
 HIV-TB+ 4.92 -3.58, 13.4 0.257 
 HIV+TB- 6.97 0.42, 13.5 0.037 
 HIV+TB+ 12.4 2.28, 22.5 0.016 
CD4+CD8+     
 HIV-TB+ -0.38 -2.49, 1.73 0.725 
 HIV+TB- -0.39 -1.18, 0.40 0.334 
 HIV+TB+ 2.22 -1.87, 6.31 0.288 
CD4+CD8-     
 HIV-TB+ -4.00 -17.9, 9.91 0.573 
 HIV+TB- -23.8 -33.7, -13.8 <0.001 
 HIV+TB+ -30.5 -41.3, -19.6 <0.001 
CD4-CD8-     
 HIV-TB+ 0.45 -13.2, 14.1 0.949 
 HIV+TB- 13.6 3.31, 23.8 0.010 
 HIV+TB+ 11.8 -4.45, 28.0 0.155 
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Supplementary Table S3 Multivariable negative binomial model assessing relationship 
between iNKT cell frequency and TB-IRIS status.  
 
 
 
 
 
aadjusted for age and sex 
 
  
Unadjusted  Coefficient 95% CI p value 
 3.99 1.18, 13.5 0.026 
Adjusteda Coefficient 95% CI p value 
 4.13 1.23, 13.9 0.022 
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Supplementary Table S4 Multivariate linear regression model to estimate the difference in 
CD4/CD8 cell subset percentage between TB IRIS and non-IRIS patients, adjusted for time.  
 
 
 
 
 
 
 
 
 
 
  
 Difference in cell subset 
percentage (TB-IRIS vs 
non-IRIS) 
95% CI p value 
CD4-CD8+ -3.02 -14.4, 8.36 0.603 
CD4+CD8+ 1.03 -10.5, 12.6 0.861 
CD4+CD8- -6.64 -12.0, -1.28 0.015 
CD4-CD8- 8.63 -5.49, 22.2 0.231 
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Supplementary Figures 
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